Recent Posts

Archives

Categories

Kazia begins phase II study into paxalisib + a keto diet to treat brain cancer

AdobeStock_261939312

Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)

Posted on . Updated on by Cherie Hartley

Kazia (ASX: KZA) CEO Dr James Garner discusses the enrolment of the first patient into their phase II study of paxalisib in combination with a ketogenic diet to treat glioblastoma (brain cancer)

 

Posted in Newsletter March 2022

IR Department acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Subscribe

Site Map Privacy Search
IR Department . All rights reserved. - Site by